α硫辛酸联合麦地参肾消胶囊对绝经后女性2型糖尿病肾病患者疗效及GDF-15的影响
|
摘要
目的探究采用α硫辛酸联合麦地参肾消胶囊对绝经后女性2型糖尿病肾病治疗效果及肾损害相关指标、生长分化因子15(GDF-15)的影响。方法选取2型糖尿病肾病绝经后女性患者67例,按随机对照原则分为两组,对照组采用α硫辛酸注射液治疗,研究组在此基础上配合麦地参肾消胶囊。收集两组患者性别、年龄、病程等基本资料,同时测定血压、糖脂指标,参照《中药新药临床研究指导原则》判定临床疗效,测定治疗前后肾损害相关指标,采用酶联免疫吸附试验检测各组患者血浆中GDF-15的浓度。结果研究组治疗有效率90.62%(29/32)高于对照组治疗有效率71.43%(25/35),差异有统计学意义(P<0.05);与治疗前比较,两组治疗后尿微量白蛋白、血浆GDF-15及24h尿蛋白定量显著降低(P<0.05),肾小球滤过率显著升高(P<0.05);组间治疗后比较,研究组肾损害相关指标及血浆GDF-15较对照组改善更明显,差异具有统计学意义(P<0.05)。结论采用α硫辛酸联合麦地参肾消胶囊对绝经后女性2型糖尿病肾病患者疗效显著,能减轻肾损害,降低GDF-15含量,值得临床推广应用。
Objective To explore the effects of alpha lipoic acid combined with maidishen Shenxiao Capsule in the treatment of postmenopausal women with type 2 diabetic nephropathy and influences on renal damage index,GDF-15. Methods A total of 67 postmenopausal women with type 2 diabetic nephropathy were selected,and randomly divided into two groups. The control group were treated with alpha lipoic acid injection therapy,the study group were treated with the Medina ginseng Shenxiao capsule on the basis of alpha lipoic acid injection. The data of gender,age and course of disease and other basic information,and the blood pressure,lipid index were collected. Clinical efficacy was measured according to the " standard" guiding principles of clinical research on new drugs,and before and after treatment of renal damage index was measured too. The level of GDF-15 was measured by enzyme-linked immunosorbent assay in each group. Results The effective rate of the treatment group was90. 62%( 29 /32),higher than that of the control group( 71. 43%,25 /35). Compared with before treatment,urinary microalbumin,plasma GDF-15 and 24 h urinary protein after treatment were significantly decreased( P<0. 05),and Glomerular filtration rate was significantly increased( P<0. 05) in the two groups after treatment. Compared with the control group,the levels of GDF-15 in the study group were significantly higher than those in the control group( P<0. 05),and the differences were statistically significant. Conclusion The effect on alpha lipoic acid combined with Maidishen Shenxiao capsule in the treatment of postmenopausal women with type 2 diabetic nephropathy patients is significant,and it can reduce renal damage and the content of GDF-15. It is worthy of clinical promotion.
Objective To explore the effects of alpha lipoic acid combined with maidishen Shenxiao Capsule in the treatment of postmenopausal women with type 2 diabetic nephropathy and influences on renal damage index,GDF-15. Methods A total of 67 postmenopausal women with type 2 diabetic nephropathy were selected,and randomly divided into two groups. The control group were treated with alpha lipoic acid injection therapy,the study group were treated with the Medina ginseng Shenxiao capsule on the basis of alpha lipoic acid injection. The data of gender,age and course of disease and other basic information,and the blood pressure,lipid index were collected. Clinical efficacy was measured according to the " standard" guiding principles of clinical research on new drugs,and before and after treatment of renal damage index was measured too. The level of GDF-15 was measured by enzyme-linked immunosorbent assay in each group. Results The effective rate of the treatment group was90. 62%( 29 /32),higher than that of the control group( 71. 43%,25 /35). Compared with before treatment,urinary microalbumin,plasma GDF-15 and 24 h urinary protein after treatment were significantly decreased( P<0. 05),and Glomerular filtration rate was significantly increased( P<0. 05) in the two groups after treatment. Compared with the control group,the levels of GDF-15 in the study group were significantly higher than those in the control group( P<0. 05),and the differences were statistically significant. Conclusion The effect on alpha lipoic acid combined with Maidishen Shenxiao capsule in the treatment of postmenopausal women with type 2 diabetic nephropathy patients is significant,and it can reduce renal damage and the content of GDF-15. It is worthy of clinical promotion.
引文
[1]杨娟,谈敏,胡群力.绝经后妇女2型糖尿病肾病患者骨代谢指标变化分析[J].中国医学创新,2014,11(26):10-12.
[2]刘云涛.血清生长分化因子-15与2型糖尿病肾病的相关性[J].广东医学,2012,33(12):1759-1761.
[3]黄雌友,姚伟峰.α-硫辛酸联合替米沙坦治疗2型糖尿病早期肾病疗效观察[J].现代中西医结合杂志,2012,21(25):2799-2800.
[4]朱成英,李鸣,莫艳新.糖尿病肾病病因病机探讨[J].河南中医,2010,11(30):1050-1051.
[5]American Diabetes Association.Standards of medical care in diabetes2007[J].Diabetes Care,2011,34(Suppl 1):S11-S61.
[6]李毅鸣,刘民生,龚政.血管紧张素Ⅱ受体拮抗剂与血管内皮功能[J].中国中医药咨讯,2010,2(15):107-108.
[7]韩俊霞,成兴波,熊佩华,等.2型糖尿病巨噬细胞抑制因子-1水平的改变及其临床意义[J].中国糖尿病杂志,2013,21(3):226-228.
[8]顾宇英,赵荫涛,宗明,等.上海地区汉族健康人群血清GDF-15水平分析[J].同济大学学报(医学版),2010,31(3):96-99.
[9]陈关芬,廖媛晖,吴海鹰,等.α-硫辛酸对2型糖尿病早期肾病保护作用的探讨[J].昆明医学院学报,2011,32(3):49-51.
[10]蔡镇.莲子清心饮对糖尿病肾病临床疗效及24 h尿蛋白定量的影响[J].中医药信息,2016,33(2):66-68.
[11]吴薇.糖尿病肾病中医辨证分型与胰岛素抵抗的相关性研究[D].南京:南京中医药大学,2008.
[12]田嘉嘉.α硫辛酸治疗2型糖尿病早期肾病疗效观察[J].医学信息,2014,28(26):635-636.
[2]刘云涛.血清生长分化因子-15与2型糖尿病肾病的相关性[J].广东医学,2012,33(12):1759-1761.
[3]黄雌友,姚伟峰.α-硫辛酸联合替米沙坦治疗2型糖尿病早期肾病疗效观察[J].现代中西医结合杂志,2012,21(25):2799-2800.
[4]朱成英,李鸣,莫艳新.糖尿病肾病病因病机探讨[J].河南中医,2010,11(30):1050-1051.
[5]American Diabetes Association.Standards of medical care in diabetes2007[J].Diabetes Care,2011,34(Suppl 1):S11-S61.
[6]李毅鸣,刘民生,龚政.血管紧张素Ⅱ受体拮抗剂与血管内皮功能[J].中国中医药咨讯,2010,2(15):107-108.
[7]韩俊霞,成兴波,熊佩华,等.2型糖尿病巨噬细胞抑制因子-1水平的改变及其临床意义[J].中国糖尿病杂志,2013,21(3):226-228.
[8]顾宇英,赵荫涛,宗明,等.上海地区汉族健康人群血清GDF-15水平分析[J].同济大学学报(医学版),2010,31(3):96-99.
[9]陈关芬,廖媛晖,吴海鹰,等.α-硫辛酸对2型糖尿病早期肾病保护作用的探讨[J].昆明医学院学报,2011,32(3):49-51.
[10]蔡镇.莲子清心饮对糖尿病肾病临床疗效及24 h尿蛋白定量的影响[J].中医药信息,2016,33(2):66-68.
[11]吴薇.糖尿病肾病中医辨证分型与胰岛素抵抗的相关性研究[D].南京:南京中医药大学,2008.
[12]田嘉嘉.α硫辛酸治疗2型糖尿病早期肾病疗效观察[J].医学信息,2014,28(26):635-636.